Baird served as a co-manager in this offering.
AboutBioMed Realty Trust, Inc. (NYSE: BMR) (“BioMed” or the “Company”) recently completed a follow-on offering of 17,250,000 shares, including full exercise of the over-allotment option, of its common stock at $17.50 per share, generating gross proceeds of approximately $301.9 million. BioMed expects to use the net proceeds from this offering to fund a portion of the purchase price of recently announced acquisitions, repay a portion of the outstanding indebtedness under its $720.0 million unsecured line of credit and for other general corporate and working capital purposes.
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The Company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 75 properties, representing 122 buildings with approximately 11.2 million rentable square feet. The Company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research.
For additional information about this transaction, please contact:
- September 2010
- BioMed Realty Trust, Inc.
- Real Estate
- Target Location
- North America